BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of ...

Eli Lilly seems to have responded to the threat by President Donald Trump of tariffs on the pharma industry if they don't relocate their manufacturing operations to the US. The pharma group has ...

The ACS Women Chemists Committee (WCC) and Eli Lilly and Company sponsor a program to provide funding for undergraduate, graduate, and postdoctoral female chemists to travel to meetings to present the ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.